SEM Latest Report

Financial Performance

Select Medical's total operating revenue was -122,587,000 yuan as of December 31, 2024, up 56,638,000 yuan from -179,225,000 yuan as of December 31, 2023, indicating an improvement in the company's revenue, albeit still negative, suggesting some progress in revenue recovery.

Key Financial Data

1. Revenue Improvement: Select Medical's total operating revenue showed a decrease in the negative value, indicating a recovery in market demand or an improvement in operating efficiency.

2. Operating Expense Control: The company may have effectively controlled marketing, sales, and general management expenses, leading to a relative increase in revenue.

3. Market Environment Change: The overall recovery of the medical industry or policy support may have contributed to the company's revenue growth.

4. Fluctuation in Non-Current Operating Income: The non-current operating income in the 2024 report was 223,414,000 yuan, providing support for the company's overall financial situation.

Peer Comparison

1. Industry-wide Analysis: The medical industry gradually recovered from the pandemic, with overall operating revenue affected by market demand and policy support. Many companies performed better in 2024 than in 2023.

2. Peer Evaluation Analysis: Compared with other companies in the same industry, Select Medical showed resilience in revenue recovery, although still in the negative area, with its revenue improvement possibly in the middle to upper level, indicating its competitiveness in the market.

Summary

From Select Medical's financial data, although the operating revenue is still negative, the company has shown positive trends in revenue improvement. Effective expense control, recovering market demand, and growth in non-current operating income have all supported the company's overall financial situation. Against the backdrop of industry recovery, Select Medical has the opportunity to further enhance its market performance.

Opportunities

1. Continuous improvement in market share, with revenue expected to maintain stable growth from 2024 to 2026.

2. The overall recovery of the medical industry and the rebound in surgical volume demand will drive the growth of high-value consumables.

3. Policy support and innovation in the medical device industry will bring more market opportunities for the company.

4. Select Medical's market strategy adjustment and product introduction will enrich its treatment pipeline and enhance competitiveness.

Risks

1. Although revenue has improved, the negative value still exists, indicating that the company still faces challenges in profitability.

2. Pressure on medical insurance spending may affect overall revenue growth, especially in the second half of the year.

3. Competitors' technological innovation and market strategies may pose a challenge to Select Medical.

4. Fluctuations in market demand may affect the sustainability of the company's revenue, and external economic changes need to be monitored.